Noxopharm Limited

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology). Noxopharm’s management team has extensive and highly relevant experience spanning a wide range of activities, including over 100 years of combined pharma experience, 20+ drug launches in numerous therapeutic areas, involvement in more than 100 clinical trials, 60+ years of academic research and 150+ peer-reviewed publications. A core strength at all levels of the company is a focus on external collaborations, whether with research institutions and academia, suppliers or industry partners both in Australia and overseas. These relationships enable Noxopharm and its network to efficiently develop new proprietary assets that have demonstrable commercial potential. Likes and shares are not endorsements